Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Xponance Inc.

Xponance Inc. boosted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 6.2% in the 4th quarter, Holdings Channel reports. The firm owned 42,409 shares of the company’s stock after purchasing an additional 2,489 shares during the period. Xponance Inc.’s holdings in Moderna were worth $4,218,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently bought and sold shares of MRNA. Norges Bank purchased a new stake in shares of Moderna in the fourth quarter valued at about $628,359,000. Renaissance Technologies LLC raised its stake in Moderna by 108.2% during the 1st quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after acquiring an additional 1,984,458 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in Moderna by 77.3% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after acquiring an additional 1,690,341 shares during the period. Morgan Stanley lifted its position in Moderna by 19.1% during the 4th quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock worth $752,133,000 after acquiring an additional 670,284 shares during the period. Finally, Invesco Ltd. grew its stake in shares of Moderna by 19.8% in the 3rd quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after purchasing an additional 517,683 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Activity at Moderna

In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the completion of the transaction, the director now owns 2,056,931 shares of the company’s stock, valued at $212,645,526.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the transaction, the director now owns 2,056,931 shares of the company’s stock, valued at $212,645,526.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 705 shares of the firm’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $101.93, for a total value of $71,860.65. Following the sale, the chief financial officer now owns 5,048 shares in the company, valued at approximately $514,542.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,954 shares of company stock valued at $11,533,976. 15.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

MRNA has been the subject of several analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price target on shares of Moderna in a research note on Thursday, March 28th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. HSBC reiterated a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Finally, Canaccord Genuity Group boosted their target price on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $126.49.

Moderna Price Performance

Moderna stock opened at $101.41 on Friday. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $144.43. The firm’s 50-day simple moving average is $100.63 and its 200 day simple moving average is $93.57. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same quarter in the prior year, the firm earned $3.61 earnings per share. The company’s revenue for the quarter was down 44.9% compared to the same quarter last year. On average, equities analysts predict that Moderna, Inc. will post -7.51 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.